17-AAG – 10 mg

Brand:
Cayman
CAS:
75747-14-7
Storage:
-20
UN-No:
Non-Hazardous - /

17-AAG is an inhibitor of heat shock protein 90 (Hsp90) and a derivative of geldanamycin (Item No. 13355) that selectively inhibits BT474 tumor cell Hsp90 over fibroblast Hsp90 (IC50s = 5 and 943 nM, respectively).{46058} It inhibits the growth of prostate cancer cell lines (IC50s = 25-45 nM) and promotes the degradation of HER2 and induces growth arrest and apoptosis in breast cancer cells overexpressing HER2 (IC50s = 4-72 nM).{20728,20725} In vivo, 17-AAG (25 mg/kg, i.p.) reduces tumor size in a G-415 gallbladder cancer mouse xenograft model.{46059}  

 

Available on backorder

SKU: 11039 - 10 mg Category:

Description

An inhibitor of Hsp90 (IC50s = 5 and 943 nM for BT474 tumor cell and fibroblast Hsp90, respectively); inhibits the growth of prostate cancer cell lines (IC50s = 25-45 nM); promotes the degradation of HER2 and induces growth arrest and apoptosis in breast cancer cells overexpressing HER2 (IC50s = 4-72 nM); reduces tumor size in a G-415 gallbladder cancer mouse xenograft model at 25 mg/kg ,


Formal name: 17-demethoxy-17-(2-propenylamino)-geldanamycin

Synonyms:  BMS 722782|CP 127374|KOS 953|NSC 330507|Tanespimycin

Molecular weight: 585.7

CAS: 75747-14-7

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|Heat Shock Proteins||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Cell Biology|Cell Death|Apoptosis||Research Area|Cell Biology|Cellular Chaperones